MiR-200c and HuR in ovarian cancer

BackgroundMicroRNAs in solid malignancies can behave as predictors of either good or poor outcome. This is the case with members of the miR-200 family, which are the primary regulators of the epithelial to mesenchymal transition and have been reported to act as both oncogenes and tumor suppressors. This study assessed the role of miR-200c as regulator of class III β-tubulin (TUBB3), a factor associated with drug-resistance and poor prognosis in ovarian cancer.MethodsExpression of miR-200c was assessed in a panel of ovarian cancer cell lines with inherent or acquired drug-resistance. Stable overexpression of miR-200c was obtained in A2780 and Hey cell lines. Crosslinking-coupled affinity purification method and ribonucleic-immunoprecipitation assay were used to characterise the complexes between miR-200c, HuR and 3′UTR region of TUBB3 mRNA. Nanofluidic technology and immunohistochemistry were used to analyze the expression of HuR, TUBB3 and miR-200c in 220 ovarian cancer patients.ResultsIn a panel of ovarian adenocarcinoma cell lines, we observed a direct correlation between miR-200c expression and chemoresistance. In A2780 cells miR-200c targeted TUBB3 3′UTR, while a positive correlation was observed between miR-200c and TUBB3 expression in most of the other cell lines. Through the analysis of 3′UTR-associated complexes, we found that the miR-200c can increase the association of the RNA binding protein HuR with TUBB3 mRNA, whereas HuR binding enhanced TUBB3 mRNA translation. Most importantly, in our analysis on 220 ovarian cancer patients we observed that overexpression of miR-200c correlated with poor or good outcome depending on the cellular localization of HuR.ConclusionThis study suggests a model for the combined regulatory activity of miR-200c and HuR on TUBB3 expression in ovarian cancer. When HuR is nuclear, high expression of miR-200c inhibits TUBB3 expression and results in a good prognosis, whereas when HuR occurs in cytoplasm, the same miRNA enhances TUBB3 expression and produces a poor outcome. These findings reveal the usefulness of multidimensional analysis in the investigation of the prognostic role of miRNA expression.

[1]  E. Martinelli,et al.  Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  S. Vasudevan,et al.  Post-transcriptional stimulation of gene expression by microRNAs. , 2013, Advances in experimental medicine and biology.

[3]  Uwe Ohler,et al.  Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. , 2011, Molecular cell.

[4]  E. Martinelli,et al.  Class III β‐tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer , 2012, Journal of cellular physiology.

[5]  J. Steitz,et al.  AU-Rich-Element-Mediated Upregulation of Translation by FXR1 and Argonaute 2 , 2007, Cell.

[6]  C. Croce,et al.  MicroRNA signatures in human ovarian cancer. , 2007, Cancer research.

[7]  Jae Hoon Kim,et al.  MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.

[8]  Enrica Calura,et al.  Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. , 2011, The Lancet. Oncology.

[9]  Simone Brabletz,et al.  The ZEB/miR‐200 feedback loop—a motor of cellular plasticity in development and cancer? , 2010, EMBO reports.

[10]  E. Berns,et al.  Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. , 2010, The international journal of biochemistry & cell biology.

[11]  G. Scambia,et al.  Molecular mechanisms of patupilone resistance. , 2008, Cancer research.

[12]  E. Pasquier,et al.  Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. , 2007, Cancer research.

[13]  R. Agami,et al.  MicroRNA regulation by RNA-binding proteins and its implications for cancer , 2011, Nature Reviews Cancer.

[14]  E. Berns,et al.  MicroRNAs in ovarian cancer biology and therapy resistance. , 2010, The international journal of biochemistry & cell biology.

[15]  G. Campiani,et al.  The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. , 2004, Cancer research.

[16]  S. Rosenwald,et al.  Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. , 2009, Gynecologic oncology.

[17]  W. Filipowicz,et al.  The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.

[18]  Georgia Salanti,et al.  Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. , 2006, Journal of the National Cancer Institute.

[19]  E. Martinelli,et al.  HuR regulates beta-tubulin isotype expression in ovarian cancer. , 2010, Cancer research.

[20]  B. Martínez-Delgado,et al.  The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. , 2010, Endocrine-Related Cancer.

[21]  Zhihui Feng,et al.  A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. , 2009, Gynecologic oncology.

[22]  G. Song,et al.  Role of hypoxia in the hallmarks of human cancer , 2009, Journal of cellular biochemistry.

[23]  R. Broaddus,et al.  Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel , 2012, Molecular Cancer Therapeutics.

[24]  E. Pasquier,et al.  Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung Cancer , 2007 .

[25]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[26]  E. Howe,et al.  Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers , 2009, Journal of oncology.

[27]  E. Martinelli,et al.  Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients , 2006, Clinical Cancer Research.

[28]  Kotb Abdelmohsen,et al.  Posttranscriptional regulation of cancer traits by HuR , 2010, Wiley interdisciplinary reviews. RNA.

[29]  G. Scambia,et al.  Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. , 2008, Gene.

[30]  S. Nordeen,et al.  MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents , 2009, Molecular Cancer Therapeutics.